1
|
Orlandi R, Leuzzi G, Lorenzini D, Rolli L, Ferrari M, Conca E, Pastorino U. Catching a shark while looking for flounders. JTCVS Tech 2023; 21:215-220. [PMID: 37854795 PMCID: PMC10580098 DOI: 10.1016/j.xjtc.2023.06.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 06/24/2023] [Accepted: 06/29/2023] [Indexed: 10/20/2023] Open
Affiliation(s)
- Riccardo Orlandi
- Department of Thoracic Surgery, University of Milan, Milan, Italy
| | - Giovanni Leuzzi
- Division of Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
| | - Daniele Lorenzini
- Division of Pathology, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
| | - Luigi Rolli
- Division of Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
| | - Michele Ferrari
- Division of Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
| | - Elena Conca
- Division of Pathology, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
| | - Ugo Pastorino
- Division of Thoracic Surgery, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy
| |
Collapse
|
2
|
Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, Langer CJ, McPherson JM, Montaner LJ, Albelda SM. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013; 2:e26218. [PMID: 24179709 PMCID: PMC3812201 DOI: 10.4161/onci.26218] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Revised: 08/05/2013] [Accepted: 08/06/2013] [Indexed: 12/14/2022] Open
Abstract
We evaluated a neutralizing anti-TGFβ antibody (GC1008) in cancer patients with malignant pleura mesothelioma (MPM). The goal of this study was to assess immunoregulatory effects in relation to clinical safety and clinical response. Patients with progressive MPM and 1-2 prior systemic therapies received GC1008 at 3mg/kg IV over 90 min every 21 d as part of an open-label, two-center Phase II trial. Following TGFβ blockade therapy, clinical safety and patient survival were monitored along with the effects of anti-TGFβ antibodies on serum biomarkers and peripheral blood mononuclear cells (PBMC). Although designed as a larger trial, only 13 patients were enrolled when the manufacturer discontinued further development of the antibody for oncology indications. All participants tolerated therapy. Although partial or complete radiographic responses were not observed, three patients showed stable disease at 3 mo. GC1008 had no effect in the expression of NK, CD4+, or CD8+ T cell activating and inhibitory markers, other than a decrease in the expression of 2B4 and DNAM-1 on NK cells. However, serum from 5 patients showed new or enhanced levels of antibodies against MPM tumor lysates as measured by immunoblotting. Patients who produced anti-tumor antibodies had increased median overall survival (OS) (15 vs 7.5 mo, p < 0.03) compared with those who did not. To our knowledge, these data represent the first immune analysis of TGFβ- blockade in human cancer patients.
Collapse
Affiliation(s)
- James P Stevenson
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | - Hedy L Kindler
- Section of Hematology/Oncology; University of Chicago School of Medicine; Chicago, IL USA
| | | | - Jing Sun
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | - Mona Jacobs-Small
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | - Jennifer Hull
- Section of Hematology/Oncology; University of Chicago School of Medicine; Chicago, IL USA
| | - Daniel Schwed
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | - Anjana Ranganathan
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | - Kheng Newick
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | - Daniel F Heitjan
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | - Corey J Langer
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| | | | | | - Steven M Albelda
- Penn Mesothelioma and Pleural Program; Perelman School of Medicine of the University of Pennsylvania; Philadelphia, PA USA
| |
Collapse
|
3
|
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure. J Thorac Oncol 2009; 4:620-8. [DOI: 10.1097/jto.0b013e31819f2e0e] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
4
|
Shimizu Y, Dobashi K, Kusakbe T, Nagamine T, Oikawa M, Satoh T, Haga J, Ishii Y, Ohkubo T, Kamiya T, Arakawa K, Sano T, Tanaka S, Shimizu K, Matsuzaki S, Utsugi M, Mori M. In-Air Micro-Particle Induced X-ray Emission Analysis of Asbestos and Metals in Lung Tissue. Int J Immunopathol Pharmacol 2008; 21:567-76. [DOI: 10.1177/039463200802100309] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Inhalation of asbestos increases the risk of lung cancer and pulmonary fibrosis. It is difficult to directly assess the distribution and content of inhaled particles in lung tissue sections. The purpose of this study is to employ an in-air micro particle induced X-ray emission (in-air micro-PIXE) system for assessment of the spatial distribution and content of asbestos and other metals in lung tissue. A proton ion-microbeam from this system was applied to irradiate lung tissue of patients with or without asbestosis, tumor tissue from both groups, and asbestos fibers ( in vitro). The content of each element composing asbestos and those of other metals were calculated and their distribution was assessed from the characteristic X-ray pattern for each element obtained after irradiation. This in-air micro-PIXE system could identify the location of asbestos bodies composed of Si, Mg, and Fe in lung tissue sections. Macrophage and lymphocytes accumulated in that area. This new system also revealed deposits of titanium, nickel, and cobalt in the lung tissues, in addition to asbestos bodies. The Si and Fe content were higher in lungs with asbestosis than in lungs without asbestosis or in tumor tissue. Analysis of asbestos fibers composed of chrysotile, crocidolite, and amosite showed that the ratios of Si, Fe, and Mg corresponded with those for the chemical structures. In-air micro-PIXE analysis is useful for assessing the distribution and quantities of asbestos bodies and also other metals in lung tissue comparing to immune-related cell localizations, and is also useful for analysis of standard asbestos fibers.
Collapse
Affiliation(s)
| | - K. Dobashi
- Gunma University Faculty of Health Science
| | - T. Kusakbe
- 21st Century COE Program, Gunma University Faculty of Health Science, Gunma
| | - T. Nagamine
- 21st Century COE Program, Gunma University Faculty of Health Science, Gunma
| | - M. Oikawa
- 21st Century COE Program, Gunma University Faculty of Health Science, Gunma
| | - T. Satoh
- Japan Atomic Energy Agency, Takasaki Advanced Radiation Research Institute, Gunma
| | - J. Haga
- Japan Atomic Energy Agency, Takasaki Advanced Radiation Research Institute, Gunma
| | - Y. Ishii
- Japan Atomic Energy Agency, Takasaki Advanced Radiation Research Institute, Gunma
| | - T. Ohkubo
- Japan Atomic Energy Agency, Takasaki Advanced Radiation Research Institute, Gunma
| | - T. Kamiya
- Japan Atomic Energy Agency, Takasaki Advanced Radiation Research Institute, Gunma
| | - K. Arakawa
- Japan Atomic Energy Agency, Takasaki Advanced Radiation Research Institute, Gunma
| | - T. Sano
- Department of Tumor Pathology, Gunma University Graduate School of Medicine
| | - S. Tanaka
- Department of General Surgical Science, Gunma University Graduate School of Medicine
| | - K. Shimizu
- Divisiont of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Gunma, Japan
| | | | | | | |
Collapse
|